Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001209943 | SCV001381399 | uncertain significance | Pierson syndrome; LAMB2-related infantile-onset nephrotic syndrome | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 588 of the LAMB2 protein (p.Pro588Ala). This variant is present in population databases (rs144324168, gnomAD 0.07%). This variant has not been reported in the literature in individuals affected with LAMB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 940370). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The alanine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001209943 | SCV002814218 | uncertain significance | Pierson syndrome; LAMB2-related infantile-onset nephrotic syndrome | 2022-02-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002561720 | SCV003716544 | uncertain significance | Inborn genetic diseases | 2022-01-25 | criteria provided, single submitter | clinical testing | The c.1762C>G (p.P588A) alteration is located in exon 14 (coding exon 14) of the LAMB2 gene. This alteration results from a C to G substitution at nucleotide position 1762, causing the proline (P) at amino acid position 588 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV003480993 | SCV004226106 | uncertain significance | not provided | 2023-01-26 | criteria provided, single submitter | clinical testing | BP4 |